New medication information in 2024: The effect of satelizumab (Anshiping) on u200bu200bthe optic nerve

Satralizumab (Satralizumab) is a therapeutic drug targeting neuroinflammatory diseases. It is mainly used to treat diseases related to the immune system, such as neuromyelitis optica (NMOSD). However, each patient's situation is unique, and the effects of medications may vary from person to person. Therefore, before considering the use of satelizumab to treat neuromyelitis optica, you should consult a medical professional to learn more about this drug, including its specific effects on the optic nerve and possible side effects.

Neuromyelitis optica is a rare but serious autoimmune disease that causes temporary or long-lasting vision loss, eye pain, and other visual disturbances. Studies have shown that satelizumab can reduce the risk of recurrence of neuromyelitis optica to some extent. According to the results of a clinical trial of satelizumab, the drug can significantly reduce the risk of seizures in NMOSD patients, including reducing the time to recovery of visual acuity related to seizures and reducing the severity of seizures. This means that by taking satelizumab, patients may be able to reduce the occurrence of vision loss and other optic nerve-related symptoms.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is120mg (1ml) per box The price may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.